Achilles Therapeutics PLC reports results for the quarter - Earnings Summary

• Achilles Therapeutics PLC ACHL.OQ reported a quarterly adjusted loss of 48 cents​​ per share for the quarter , lower than the same quarter last year, when the company reported EPS of -42 cents. The mean expectation of two analysts for the quarter was for a loss of 41 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Achilles Therapeutics PLC's reported EPS for the quarter was a loss of 48 cents​.

• The company reported a quarterly loss of $19.6 million.

• Achilles Therapeutics PLC shares had held steady so far this quarter and gained 14.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Achilles Therapeutics PLC is $2.00

This summary was machine generated from LSEG data November 14 at 02:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)